193 related articles for article (PubMed ID: 7732906)
1. Prostaglandins as ocular hypotensive agents; development of an analogue for glaucoma treatment.
Stjernschantz J
Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():63-8. PubMed ID: 7732906
[No Abstract] [Full Text] [Related]
2. [Prostaglandins - - clinical aspects in ophthalmology].
Malcea C; Nenciu A
Oftalmologia; 2006; 50(3):22-8. PubMed ID: 17144502
[No Abstract] [Full Text] [Related]
3. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma.
Borghi V; Bastia E; Guzzetta M; Chiroli V; Toris CB; Batugo MR; Carreiro ST; Chong WK; Gale DC; Kucera DJ; Jia L; Prasanna G; Ongini E; Krauss AH; Impagnatiello F
J Ocul Pharmacol Ther; 2010 Apr; 26(2):125-32. PubMed ID: 20415621
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: synthesis and biological activity.
Feng Z; Hellberg MR; Sharif NA; McLaughlin MA; Williams GW; Scott D; Wallace T
Bioorg Med Chem; 2009 Jan; 17(2):576-84. PubMed ID: 19101156
[TBL] [Abstract][Full Text] [Related]
5. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study.
Shimmyo M
Am J Ophthalmol; 2005 Jun; 139(6):1148; author reply 1148-9. PubMed ID: 15953471
[No Abstract] [Full Text] [Related]
6. Studies on ocular inflammation and development of a prostaglandin analogue for glaucoma treatment.
Stjernschantz J
Exp Eye Res; 2004 Apr; 78(4):759-66. PubMed ID: 15037110
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans.
Camras CB
Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():519-25. PubMed ID: 7732900
[No Abstract] [Full Text] [Related]
8. Is more always better?
Tuulonen A
Acta Ophthalmol Scand; 2004 Aug; 82(4):377-9. PubMed ID: 15291927
[No Abstract] [Full Text] [Related]
9. [Topical prostaglandins influence over cornea--preliminary report].
Wierzbowska J; Stankiewicz A
Klin Oczna; 2006; 108(10-12):479-81. PubMed ID: 17455732
[TBL] [Abstract][Full Text] [Related]
10. Use of a Bayesian network to predict the nighttime intraocular pressure peak from daytime measurements.
Nordmann JP; Berdeaux G
Clin Ther; 2007 Aug; 29(8):1751-60; discussion 1750. PubMed ID: 17919556
[TBL] [Abstract][Full Text] [Related]
11. Switch to latanoprost monotherapy from combined treatment with beta-antagonist and other antiglaucoma agents in patients with glaucoma or ocular hypertension.
Ito K; Goto R; Matsunaga K; Sugimoto K; Uji Y
Jpn J Ophthalmol; 2004; 48(3):276-80. PubMed ID: 15175922
[TBL] [Abstract][Full Text] [Related]
12. Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open-angle glaucoma.
Hotehama Y; Mishima HK; Kitazawa Y; Masuda K
Jpn J Ophthalmol; 1993; 37(3):270-4. PubMed ID: 8295364
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication.
Magacho L; Reis R; Shetty RK; Santos LC; Avila MP
Ophthalmology; 2006 Mar; 113(3):442-5. PubMed ID: 16458964
[TBL] [Abstract][Full Text] [Related]
15. New prostaglandin derivative for glaucoma treatment.
Perrino E; Uliva C; Lanzi C; Soldato PD; Masini E; Sparatore A
Bioorg Med Chem Lett; 2009 Mar; 19(6):1639-42. PubMed ID: 19233645
[TBL] [Abstract][Full Text] [Related]
16. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study.
Brandt JD; Beiser JA; Gordon MO; Kass MA;
Am J Ophthalmol; 2004 Nov; 138(5):717-22. PubMed ID: 15531304
[TBL] [Abstract][Full Text] [Related]
17. Prostanoids for the management of glaucoma.
Arranz-Marquez E; Teus MA
Expert Opin Drug Saf; 2008 Nov; 7(6):801-8. PubMed ID: 18983226
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacodynamics and pharmacokinetics of prostaglandins and their derivates in eye tissues].
Szaliński MR; Turno-Krecicka A
Klin Oczna; 2001; 103(4-6):203-5. PubMed ID: 11975019
[TBL] [Abstract][Full Text] [Related]
19. Latanoprost therapy in patients with glaucoma and ocular hypertension inadequately controlled with carteolol.
Yasar T; Ozdemir M; Andi I; Ozdemir G; Simsek S
Jpn J Ophthalmol; 2004; 48(2):172-3. PubMed ID: 15060799
[No Abstract] [Full Text] [Related]
20. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
